Valuation: Healios K.K.

Market Cap 33.75B 209M 183M 168M 157M 297M 19.93B 302M 2.02B 785M 9.79B 786M 769M P/E 2026 *
-6.86x
P/E 2027 * -12.2x
Enterprise Value 33.49B 208M 182M 167M 156M 295M 19.77B 299M 2B 779M 9.72B 779M 763M EV / Sales 2026 *
55.6x
EV / Sales 2027 * 3.86x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
1 day+2.40%
1 week+0.79%
Current month+1.19%
1 month-13.22%
3 months-31.00%
6 months-8.90%
Current year-6.57%
1 week 247
Extreme 247
263
1 month 234
Extreme 234
309
Current year 234
Extreme 234
483
1 year 234
Extreme 234
747
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 72 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%+0.79%-40.05%-4.83% 209M
+0.68%+5.92%+77.86%+136.97% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
+3.14%+9.35%+54.01%+0.99% 19.69B
-0.29%+9.78%+43.90%-29.12% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+6.81%+21.90%+50.68% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +2.59%+7.87%+47.16%+129.66% 24.57B
Weighted average by Cap. +2.28%+6.47%+59.87%+136.18%

Financials

2026 *2027 *
Net sales 602M 3.73M 3.26M 3M 2.8M 5.3M 356M 5.38M 36.01M 14M 175M 14.02M 13.71M 9.12B 56.54M 49.43M 45.42M 42.34M 80.31M 5.38B 81.52M 545M 212M 2.65B 212M 208M
Net income -4.77B -29.58M -25.86M -23.77M -22.15M -42.02M -2.82B -42.65M -285M -111M -1.38B -111M -109M -2.94B -18.26M -15.96M -14.67M -13.67M -25.93M -1.74B -26.33M -176M -68.46M -855M -68.54M -67.07M
Net Debt -260M -1.61M -1.41M -1.29M -1.21M -2.29M -153M -2.32M -15.54M -6.04M -75.39M -6.05M -5.92M 1.46B 9.07M 7.93M 7.29M 6.79M 12.88M 864M 13.08M 87.49M 34.01M 425M 34.05M 33.32M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-07-05 JP¥256.00 +2.40% 520,600
26-07-03 JP¥250.00 -1.96% 1,096,500
26-07-02 JP¥255.00 -0.78% 525,700
26-07-01 JP¥257.00 +1.58% 528,200
26-06-30 JP¥253.00 -0.39% 497,100
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
250.00JPY
Average target price
779.83JPY
Spread / Average Target
+211.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock